SG10201406063XA - Drug fusions and conjugates with extended half life - Google Patents

Drug fusions and conjugates with extended half life

Info

Publication number
SG10201406063XA
SG10201406063XA SG10201406063XA SG10201406063XA SG10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA SG 10201406063X A SG10201406063X A SG 10201406063XA
Authority
SG
Singapore
Prior art keywords
conjugates
half life
extended half
drug fusions
fusions
Prior art date
Application number
SG10201406063XA
Inventor
Bruce Hamilton
Christopher Herring
Mark Andrew Paulik
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG10201406063XA publication Critical patent/SG10201406063XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG10201406063XA 2009-09-30 2010-09-23 Drug fusions and conjugates with extended half life SG10201406063XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24734609P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
SG10201406063XA true SG10201406063XA (en) 2014-11-27

Family

ID=43130084

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201406063XA SG10201406063XA (en) 2009-09-30 2010-09-23 Drug fusions and conjugates with extended half life

Country Status (13)

Country Link
US (2) US20120276098A1 (en)
EP (1) EP2483308A1 (en)
JP (1) JP2013506628A (en)
KR (1) KR20120092611A (en)
CN (2) CN104147611A (en)
AU (1) AU2010303112A1 (en)
BR (1) BR112012007374A2 (en)
CA (1) CA2774552A1 (en)
EA (1) EA201290123A1 (en)
IL (1) IL218651A0 (en)
MX (1) MX2012003939A (en)
SG (1) SG10201406063XA (en)
WO (1) WO2011039096A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075505A1 (en) 2009-02-19 2011-04-06 Glaxo Group Ltd VARIATIONS FROM UNION TO ANTI- IMPROVED SERUM ALBUMIN
EA021146B1 (en) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Drug fusions and conjugates
NZ603267A (en) * 2010-04-27 2014-12-24 Chr Hansen As Method for inoculating yeast into fruit juice
AU2011254559B2 (en) * 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
JP2013538566A (en) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Improved antiserum albumin binding variants
CN102718868A (en) * 2011-03-30 2012-10-10 上海华谊生物技术有限公司 Fixed point mono-substituted pegylation of Exendin analogue and preparation method thereof
WO2012136792A2 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
US9382304B2 (en) 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
CN102382191A (en) * 2011-09-23 2012-03-21 江南大学 Preparation method and application of novel braingutpeptide stimulant molecule
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
UY35144A (en) * 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
AR094181A1 (en) 2012-12-21 2015-07-15 Sanofi Sa GLP1 / GIP OR TRIGONAL DUAL AGONISTS OF GLP1 / GIP / GLUCAGON
WO2014118220A1 (en) * 2013-01-31 2014-08-07 Glaxo Group Limited Method of producing a protein
US20160108098A1 (en) 2013-05-02 2016-04-21 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
BR112016004355A2 (en) * 2013-08-30 2017-10-17 Aprilbio Co Ltd fab antiserumbumin effector fusion construct and method of preparation thereof
EP3043824B1 (en) 2013-09-13 2022-07-06 The Scripps Research Institute Modified therapeutic agents and compositions thereof
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US20170327577A1 (en) * 2014-06-06 2017-11-16 The California Institute For Biomedical Research Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN111388680B (en) * 2015-01-28 2024-01-05 中国科学院天津工业生物技术研究所 Application of polypeptide complex as polypeptide or protein drug carrier, method and fusion protein complex thereof
CN107743494B (en) * 2015-06-02 2022-04-29 诺和诺德股份有限公司 Insulin with polar recombinant extensions
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
MA43348A (en) 2015-10-01 2018-08-08 Novo Nordisk As PROTEIN CONJUGATES
US11414480B2 (en) 2016-12-07 2022-08-16 Ablynx N.V. Serum albumin binding immunoglobulin single variable domains
EP3554546A4 (en) * 2016-12-14 2021-04-14 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
SG10202108972RA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
JP7300385B2 (en) 2017-01-17 2023-06-29 アブリンクス エン．ヴェー． improved serum albumin binder
WO2018140456A1 (en) * 2017-01-24 2018-08-02 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
CN108440668A (en) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 The fusion protein of FGF21 and IGF-1 and its application
JP2020513019A (en) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス Oligomer-extended insulin-Fc conjugate
EP3684816A1 (en) 2017-09-22 2020-07-29 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
CN108426995A (en) * 2018-02-26 2018-08-21 徐州医科大学 A kind of cell elution process based on the drug target residence time
US11780900B2 (en) 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202014433A (en) * 2018-04-25 2020-04-16 比利時商健生藥品公司 Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
CN111234015B (en) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 Antibody for prolonging half life of medicine, fusion protein and application thereof
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of recombinant proteins with different binding sites
EP0464022B1 (en) 1989-03-20 2000-05-31 The General Hospital Corporation Insulinotropic hormone
ES2113879T3 (en) 1990-01-24 1998-05-16 Douglas I Buckley GLP-1 ANALOGS USEFUL FOR THE TREATMENT OF DIABETES.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
DK36492D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As PREPARATION
ATE417622T1 (en) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc REGULATION OF GASTROINTESTINAL MOBILITY
DE69838521T2 (en) 1997-07-07 2008-05-21 Medical Research Council Method for increasing the concentration of nucleic acid molecules
EP1019077B2 (en) 1997-08-08 2010-12-22 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
BR9814189A (en) 1997-11-14 2000-10-03 Amylin Pharmaceuticals Inc "exendin agonist compounds"
EP1066314B1 (en) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
KR100942864B1 (en) 2000-12-07 2010-02-17 일라이 릴리 앤드 캄파니 GLP-1 Fusion Proteins
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
JP5424521B2 (en) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Albumin fusion protein
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
SI2932981T1 (en) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
EP1784427A2 (en) 2004-06-01 2007-05-16 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
NZ555464A (en) * 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
AU2008334605B2 (en) * 2007-12-13 2013-07-18 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2009121804A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
UY32452A (en) * 2009-02-19 2010-09-30 Glaxo Group Ltd IMPROVED SERUM ANTI-ALBUMIN VARIANTS IMPROVED
AR075505A1 (en) * 2009-02-19 2011-04-06 Glaxo Group Ltd VARIATIONS FROM UNION TO ANTI- IMPROVED SERUM ALBUMIN
EA021146B1 (en) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Drug fusions and conjugates

Also Published As

Publication number Publication date
CA2774552A1 (en) 2011-04-07
MX2012003939A (en) 2012-07-30
US20120276098A1 (en) 2012-11-01
JP2013506628A (en) 2013-02-28
AU2010303112A1 (en) 2012-04-26
CN102666586A (en) 2012-09-12
IL218651A0 (en) 2012-05-31
BR112012007374A2 (en) 2019-09-24
CN104147611A (en) 2014-11-19
EP2483308A1 (en) 2012-08-08
WO2011039096A1 (en) 2011-04-07
KR20120092611A (en) 2012-08-21
EA201290123A1 (en) 2012-10-30
US20140227264A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
IL218651A0 (en) Drug fusions and conjugates with extended half life
ZA201107022B (en) Drug fusions and conjugates
HRP20181493T1 (en) Epsilon-polylysine conjugates and use thereof
ZA201006763B (en) Drug fusions and conjugates
ZA201204480B (en) Conjugate with target-finding ligand and use thereof
SG2014012918A (en) Albumin variants and conjugates
EP2486918A4 (en) Pharmaceutical composition with both immediate and extended release characteristics
ZA201308703B (en) Novel maytansinoid derivatives with peptide linker and conjugates thereof
ZA201105623B (en) Aminopyrazine derivative and medicine
IL213848A0 (en) Fgf21 derivatives with albumin binder a-b-c-d-e-and their use
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
IL213974A0 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
EP2575887A4 (en) Optimized drug conjugates
EP2391217A4 (en) Synthetic conjugates and uses thereof
HK1178526A1 (en) Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof 8--7-
GB0906195D0 (en) Needle and syringe
IL219768A0 (en) Drug combination with thebromine and its use in therapy
IL219769A0 (en) Drug combination with theromine and its use in therapy
ZA201202203B (en) Drug fusions and conjugates with extended half life
ZA201108276B (en) Redox drug derivatives
EP2408808A4 (en) Terminally-functionalized conjugates and uses thereof
HK1218538A1 (en) Piperazine derivatives and their pharmaceutical use
TWM371940U (en) Exhibiting body with advertisement feature
GB0908338D0 (en) Redox drug derivatives
GB0900539D0 (en) Modified linkers